Picture of Neuropace logo

NPCE Neuropace Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Neuropace, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-30-24.3-36.1-47.1-33
Depreciation
Non-Cash Items4.524.4210.814.715.6
Unusual Items
Other Non-Cash Items
Changes in Working Capital0.009-2.070.368-4.79-2.48
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-25-21.6-24.6-36.9-19.7
Capital Expenditures-0.468-0.062-0.384-0.603-0.173
Purchase of Fixed Assets
Other Investing Cash Flow Items4.09-10.7-8524.423.2
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities3.62-10.8-85.423.823
Financing Cash Flow Items0-1.16-3.39-0.406-0.564
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities21.4551030.498.13
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.03822.6-7.45-12.611.5